Cancer Pill Boosts Survival in Study

Revolution Medicines' experimental oral cancer drug demonstrated a significant improvement in patient survival rates during a late-stage trial. Patients treated with the drug lived nearly twice as long as those receiving chemotherapy for pancreatic cancer. This positive outcome led to a substantial surge in the company's stock price, highlighting the potential of this novel therapeutic approach in treating advanced cancers.